Garenoxacin (BMS 284756) was active against 105 of 108 (97%) recent clinical Gardnerella vaginalis isolates at < or =2 micro g/ml by using the reference agar dilution method for anaerobes. Twenty-eight percent of isolates (31 of 108) were resistant to metronidazole, and 44% were resistant to doxycycline. All were susceptible to clindamycin and ampicillin-sulbactam.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC132768 | PMC |
| http://dx.doi.org/10.1128/AAC.46.12.3995-3996.2002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol
May 2008
Prous Science, Barcelona, Spain.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prouse Science Integrity, the drug discovery and development portal, http://integrity.prous.
View Article and Find Full Text PDFIn vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.
Antimicrob Agents Chemother
October 2005
Servicio de Dermatología, Hospital Universitario, José E. González, Madero y Gonzalitos, Col. Mitras Centro, Monterrey, NL, México.
The in vitro activities of DA-7867, a novel oxazolidinone, and garenoxacin (BMS-284756) were compared to those of linezolid in 67 susceptible and drug-resistant clinical isolates of Mycobacterium tuberculosis. DA-7867 was the most active drug with an MIC(90) of 0.125 microg/ml, compared to the MIC(90)s of 4 microg/ml of garenoxacin and 2 microg/ml of linezolid.
View Article and Find Full Text PDFPopulation pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Antimicrob Agents Chemother
December 2004
Pharmacometrics R&D, Cognigen Corporation, Buffalo, New York 14221-5831, USA.
Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed garenoxacin population pharmacokinetics and exposure-response relationships for safety (adverse effects [AE]) and antimicrobial activity (clinical cure and bacteriologic eradication of Streptococcus pneumoniae and the grouping of Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis). Data were obtained from three phase II clinical trials of garenoxacin administered orally as 400 mg once daily for 5 to 10 days for the treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis, and sinusitis.
View Article and Find Full Text PDFAntimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
Antimicrob Agents Chemother
June 2004
Royal Perth Hospital, Australia.
Between 1999 and 2001, 16,731 isolates from the Asia-Pacific Region were tested in the SENTRY Program for susceptibility to six fluoroquinolones including garenoxacin. Garenoxacin was four- to eightfold less active against Enterobacteriaceae than ciprofloxacin, although both drugs inhibited similar percentages at 1 microg/ml. Garenoxacin was more active against gram-positive species than all other fluoroquinolones except gemifloxacin.
View Article and Find Full Text PDFIn vitro activities of new antimicrobials against Nocardia brasiliensis.
Antimicrob Agents Chemother
February 2004
Laboratorio Interdisciplinario de Investigación Dermatológica, Servicio de Dermatología, Hospital Universitario, Monterrey, Nuevo León, México.
The in vitro sensitivities of 30 strains of Nocardia brasiliensis to DA-7867, gatifloxacin, moxifloxacin, and BMS-284756 (garenoxacin) were determined using the broth microdilution method. All N. brasiliensis strains were sensitive to these antimicrobials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!